Deng Lin, Luo Yingzhi, An Binyi, Su Ming, Sang Hong, Liu Fang
Department of Dermatology, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, 310006, People's Republic of China.
Department of Dermatology, Jinling Hospital, Nanjing Medical University, Nanjing, 210002, People's Republic of China.
Clin Cosmet Investig Dermatol. 2022 Nov 10;15:2421-2426. doi: 10.2147/CCID.S383327. eCollection 2022.
Palmar-plantar atopic dermatitis is a common and debilitating condition with significant diagnostic and management challenges.
The paper presents the successful treatment of dupilumab in five female patients with recalcitrant palmar-plantar atopic dermatitis.
The Hand Eczema Severity Index (HECSI) and the Foot Eczema Severity Index (FECSI), eosinophils and IgE levels were evaluated before and after the treatment.
Five recalcitrant palmar-plantar atopic dermatitis patients had substantial responses to dupilumab and the persistent pruritus was soon alleviated during the therapy. By week 16, all patients' palmar-plantar eczema has been almost clear, with significant decrease of HECSI and FECSI. The count of eosinophils and IgE levels returned to normal in all patients.
Dupilumab significantly improves disease severity and reduces eosinophils and IgE in refractory palmar-plantar AD patients.
掌跖部特应性皮炎是一种常见且使人衰弱的疾病，在诊断和管理方面存在重大挑战。
本文介绍了度普利尤单抗成功治疗五例顽固性掌跖部特应性皮炎女性患者的情况。
在治疗前后评估手部湿疹严重程度指数（HECSI）、足部湿疹严重程度指数（FECSI）、嗜酸性粒细胞和IgE水平。
五例顽固性掌跖部特应性皮炎患者对度普利尤单抗有显著反应，治疗期间持续的瘙痒很快得到缓解。到第16周时，所有患者的掌跖部湿疹几乎消退，HECSI和FECSI显著降低。所有患者的嗜酸性粒细胞计数和IgE水平均恢复正常。
度普利尤单抗可显著改善难治性掌跖部特应性皮炎患者的疾病严重程度，并降低嗜酸性粒细胞和IgE水平。
